Pila Pharma AB (“Pila Pharma” or the “Company”) published its interim report for the second half of 2025 on February 10, 2026. Below are some key points highlighted in connection with the report:
- Progress in the clinical development within erythromelalgia and obesity
- Incomplete preclinical results within obesity
- Agreement with a new CRO to prepare and submit a clinical trial application within obesity
- Stable cash position – amounted to SEK 19.3m at the end of H2-25
Preparations for a Clinical Trial Application in Erythromelalgia
On February 9, Pila Pharma announced that the Company has initiated preparations to apply for a clinical study in erythromelalgia. The disease is a rare and often severely debilitating condition characterized by neurogenically driven inflammation and disturbances in nerve and vascular function. The condition manifests as recurrent or persistent episodes of intense pain, burning sensations, increased heat, and redness, typically localized to the feet and hands but sometimes affecting other parts of the body. Current treatment focuses on symptom relief and management of triggering factors, and patients are often advised to avoid triggers such as heat, physical exertion, and pressure on affected areas, which in practice may result in significant limitations in daily life.
Pila Pharma’s candidate XEN-D0501 offers a novel approach to erythromelalgia by blocking TRPV1, a receptor that plays a central role in the nerve-driven inflammation and hypersensitivity underlying the severe pain attacks. By attenuating this overactivation, the candidate targets an underlying disease mechanism rather than merely alleviating symptoms, as is the case with current treatments. With the first clinical study in this indication now being prepared, the objective is to establish proof-of-concept by demonstrating XEN-D0501’s potential effect in reducing perceived pain in erythromelalgia.
The Company has been granted Orphan Drug Designation for XEN-D0501 by the FDA in erythromelalgia, providing benefits such as tax credits, market exclusivity in the event of approval, and a potentially faster path to commercialization. Upon successful proof-of-concept in the forthcoming clinical study, we expect Pila Pharma to also apply for orphan drug status within the EU.
In our initiation analysis of Pila Pharma, we estimated that development within erythromelalgia would be deprioritized in the coming years as the Company focused on obesity and type 2 diabetes. The announced initiation of preparations for a clinical study indicates that Pila Pharma intends to accelerate clinical development within this indication. The initial proof-of-concept study is expected to be relatively small and therefore less costly, with Analyst Group estimating a cost of approximately SEK 2–4m. At the same time, a successful study is expected to strengthen Pila Pharma’s negotiating position in potential future partnership discussions, while orphan drug status in the EU would provide additional benefits, making the study an important future value driver.
Incomplete Preclinical Results and Agreement with a New CRO
On January 26, Pila Pharma announced that the Company’s preclinical obesity studies had been completed, showing no effect on body weight in the obese rats included in the study. However, the study results are not yet finalized, and it remains unclear whether the rats were exposed to Pila Pharma’s candidate XEN-D0501. In connection with the study results, Pila Pharma also announced that the Company has entered into an agreement with a new clinical contract research organization (CRO) to prepare and submit an application for a clinical trial in obesity, which according to Analyst Group slightly reduces the execution risk.
Analyst Group assesses that the lack of observed weight reduction in the preclinical study cannot be unequivocally interpreted as a lack of efficacy, as uncertainty remains regarding actual drug exposure due to the change in formulation. The outcome of the ongoing exposure analysis will therefore be central to the continued assessment and is expected to be presented in the coming months. At the same time, Pila Pharma has already initiated preparations for clinical development in obesity through an agreement with a new CRO, indicating a continued strategic focus on the indication. Given the extensive safety documentation for XEN-D0501, a clinical study is considered to be regulatorily feasible, although continued development in the event of confirmed lack of preclinical efficacy would entail an elevated risk profile.
Costs in Line with Our Estimates
Operating expenses amounted to approximately SEK 3.5m (3.6), demonstrating solid cost control. In addition, Pila Pharma reported a shareholder contribution of approximately SEK 8.7m to a group company, which is assumed to relate to Pila Pharma’s subsidiary, as the interim report only presents the parent company’s financial statements. The contribution is assumed to be attributable to ongoing costs in the Danish subsidiary, such as the preclinical obesity study and preparations for clinical studies across all indications. Furthermore, cash in the subsidiary amounted to SEK 3.4m.
The cash balance amounted to SEK 19.3m at the end of December 2025, including the subsidiary’s cash balance, and was strengthened in August through an oversubscribed rights issue that provided Pila Pharma with net proceeds of approximately SEK 27m in August 2025. The Company has outstanding warrants of series TO2 with an exercise period of February 5–15, 2026, at a subscription price of SEK 1.50 per share. In an interview in connection with the H2 report, Pila Pharma’s CEO Gustav H. Gram stated that the Company has received indications from certain shareholders of their intention to exercise their warrants, and that both he and Chairman of the Board Dorte X. Gram intend to exercise their warrants, which instills confidence in management’s alignment with shareholders.
As Pila Pharma intends to maintain a high pace of clinical development, illustrated by preparations for a clinical study in erythromelalgia and the agreement with a CRO to prepare and submit a clinical trial application in obesity, this is expected to result in a need for additional external capital to realize the potential of the drug portfolio. Pila Pharma states that the Company is financed into 2027 based on currently planned activities; however, to complete the planned clinical studies within the respective indications, Analyst Group assesses that additional capital will be required, where the outcome of the TO2 warrants will be an important factor for the future financing needs.
In summary, Pila Pharma is maintaining a high operational pace, with completed preclinical studies and initiated preparations for clinical development in both erythromelalgia and obesity, while also expected to continue clinical development in type 2 diabetes, which together constitute strong potential value drivers going forward. We view XEN-D0501 as a scalable candidate offering a differentiated alternative compared to current therapies across the various indications. However, to accelerate clinical development according to plan, additional external capital is expected to be required, with the outcome of the TO2 warrants becoming important for the extent of any future financing needs.
Analyst Group will return with an updated equity research report on Pila Pharma.
